Prognosis of bulky pTIIB cervical cancer treated by radical hysterectomy comparing adenocarcinoma with squamous cell carcinoma using propensity score matching

Masao Okadome1 | Rina Nagayama1 | Mototsugu Shimokawa2 | Kenzo Sonoda1 | Kumi Shimamoto1 | Toshiaki Saito1

Abstract

Objective: To investigate whether radical hysterectomy (RAH) can effectively treat true Stage IIB (pTIIB) cervical adenocarcinoma (AC) because FIGO (clinical) Stage IIB cervical cancer is rarely treated with RAH and radiotherapy has unfavorable effects on AC.

Methods: We retrospectively analyzed data for 82 patients with Stage pTIIB cervical cancer who underwent RAH at our institution between January 1997 and December 2017. The end points were disease-free survival (DFS) and overall survival (OS) among squamous cell carcinoma (SCC) (n = 60) and AC (n = 22) patients. Kaplan–Meier survival analysis with and without propensity score matching was conducted to identify the impact of RAH.

Results: Para-aortic lymph node metastasis and tumor diameter were significant factors for recurrence, and adjuvant chemotherapy prevented recurrence on multivariate analysis. After propensity score matching, there was no significant difference in DFS and OS between the groups. Five-year DFS and OS of the SCC group were 0.505 (95% confidence interval [CI] 0.268–0.702) and 0.619 (95% CI 0.351–0.803), respectively, and those of the AC group were 0.444 (95% CI 0.232–0.638) and 0.602 (95% CI 0.351–0.782), respectively.

Conclusion: Bulky Stage pTIIB cervical cancer is hard to cure, but RAH plus adjuvant therapy might be an option for radio-resistant pTIIB cervical AC.

KEYWORDS
Adenocarcinoma, Cervical cancer, Concurrent chemoradiotherapy, Propensity score matching, Radical hysterectomy, Squamous cell carcinoma

1 INTRODUCTION

Most women with Stage IIB cervical cancer are treated with primary concurrent chemoradiotherapy (CCRT). Radical abdominal hysterectomy (RAH) for this disease is not performed in most countries because the late complication rate of surgery for grade 3/4 cervical cancer is greater than that for primary CCRT.1 There are different opinions regarding the treatment response of the histological...
types of cervical cancer to radiotherapy (RT). However, a large study of 64,531 patients with squamous cell carcinoma (SCC) and 7,265 with adenocarcinoma (AC) of the uterine cervix revealed that patients with AC were more likely to die than those with SCC, both before and after the era in which concurrent chemotherapy was added to primary RT.

In Japan, class III RAH including lymphadenectomy remains the standard treatment for Stage IB1 to IIB cervical cancer, regardless of the histology. RT of cervical AC seems to have a less favorable effect than that for SCC, and Japanese women with cervical AC tend to undergo RAH. The National Comprehensive Cancer Network guidelines recommend primary CCRT to treat Stage IIB cervical cancer, regardless of the histology. However, there is little information regarding the survival of patients with Stage IIB AC after primary RT/CCRT. Recently, a study on the treatment options for cervical AC reported that curative surgery improved survival in cervical AC at FIGO (the International Federation of Gynecology and Obstetrics) clinical Stage IIB when curative surgery and curative definitive CCRT were compared. It seems significant to investigate whether RAH is useful to treat Stage IIB cervical AC. In the present study, we used propensity score matching to compare the survival of patients with bulky Stage pTIIIB cervical AC or SCC treated with RAH. We focused on surgical cases with true Stage IIB (Stage pTIIIB) cancer because FIGO clinical Stage IIB disease included cases without parametrial involvement.

2 | MATERIALS AND METHODS

All procedures in the current study were conducted in accordance with the ethical standards of the Institutional Research Committee of the National Hospital Organization (NHO) Kyushu Cancer Center, the ethical guidelines of the Ministry of Health, Labor, and Welfare of Japan, and the 1964 Helsinki Declaration and its later amendments. We analyzed only the data and medical or radiological images for which the participants gave permission at their first consultation at our hospital. No patient-identifiable data were reported, and no direct interaction with patients was necessary.

This was a retrospective cohort study of patients with Stage pTIIIB cervical cancer who underwent RAH at the Gynecology Service of the NHO Kyushu Cancer Center between January 1997 and December 2017. Clinical staging was classified according to the FIGO 2008 cervical cancer staging system and histology by the World Health Organization 2003 histological classification system. We reviewed the databases of cervical cancer treatment performed by our service and identified 82 women with Stage pTIIIB cervical cancer who had undergone class III RAH including two who received class II RAH during the study period (Figure 1). For patients who underwent RAH, we reviewed their medical records from the NHO Kyushu Cancer Center. The records included treatment summaries, surgical records, pathological reports with/without images of resected uteruses, records of latest consultation, and outpatient summaries, if available, to obtain the patients’ background characteristics, laboratory data, radiological images, and complications. Tumor size and depth of stromal invasion were obtained from surgical records/pathological reports and imaging data.

Indications for postoperative RT other than Stage pTIIIB disease included full-thickness cancer invasion of the cervix and pelvic lymph node metastasis. Intravaginal brachytherapy was used when the cancer invasion was <1 cm from the vaginal margin. The range of intravaginal brachytherapy was 9 Gy/3 Fr to 30 Gy/10 Fr and each fraction was administered once weekly. Regarding the dose of conventional postoperative pelvic external RT, we used radiation doses of 40 Gy/25 Fr for the whole pelvis from 1997 to 2002, 45 Gy/25 Fr from 2002 to March 2010, and 50.4 Gy/28 Fr from April 2010 onwards. Postoperative intensity-modulated RT at 50.4 Gy/28 Fr was begun around August 2012. When the para-aortic lymph nodes (PALNs) were involved, the field of pelvic external RT was extended to these lymph nodes. The total dose of RT was 45 Gy/25 Fr in these cases. Every fraction of pelvic external RT was administered 5 days a week. Cisplatin was used in CCRT at a dose of 30 or 40 mg/m² per week for up to 6 weeks.

The reasons for adjuvant chemotherapy treatment instead of postoperative CCRT included postoperative ileus, temporary vesicovaginal fistula, ureteral injury, and pretreatment colitis episodes. The reasons for adjuvant chemotherapy being added to postoperative CCRT included AC with PALN involvement, tumors with poorly differentiated components with plural lymph node involvement, and tumors of 6 cm or larger with pelvic lymph node involvement. The patients underwent additional adjuvant chemotherapy after CCRT. Adjuvant chemotherapy regimens were as follows: paclitaxel + carboplatin, docetaxel + carboplatin, and peplomycin + ifosfamide + carboplatin. Fifteen patients with AC received paclitaxel + carboplatin, two of whom also received docetaxel + carboplatin. Eight patients with SCC received paclitaxel + carboplatin and four received peplomycin + ifosfamide + carboplatin.

We also studied the rate of complications for each histological cancer type as well as that of the total population.

Background characteristics were determined using descriptive statistics or contingency tables. The normality of numerical factors was tested using the Shapiro-Wilk normality test. Comparisons of numerical factors between SCC and AC were tested using the Mann-Whitney U test. Risk factors for recurrence were assessed using logistic regression analysis. All p values were two-sided and p < 0.05 was considered to indicate statistical significance. Cumulative distributions of disease-free survival (DFS) and overall survival (OS) were estimated using the Kaplan–Meier method. The log-rank test was used to compare differences between survival curves. A propensity score matching method with a 1:1 ratio was applied to reduce selection bias and the potential baseline differences between the SCC and AC groups. All statistical analyses were performed using EZR version 1.30 (Saitama Medical Center, Jichi Medical University, Saitama, Japan).
A schematic illustration of the patient enrollment for RAH is presented in Figure 1. Between January 1997 and December 2017, 1223 women with cervical cancer were treated by our service (Fig. 1). The number of patients with each stage is also indicated. In total, 82 patients with Stage pT2b cervical cancer were analyzed. Sixty of the 82 patients had SCC and 22 had AC. The patients with AC included one case each of serous carcinoma, endometrioid carcinoma, and adenosquamous carcinoma; the remainder were endocervical type according to the World Health Organization 2003 histological classification (Fig. 1). Two of the AC group underwent class II RAH and the remainder underwent class III RAH.

Patients’ background characteristics are shown in Table 1. The Shapiro–Wilk normality test indicated a lack of normal distribution in the follow-up period tested in Table 1; for this reason, the Mann-Whitney U test was adopted to compare the follow-up periods between the SCC and AC groups. Other nominal factors were analyzed using Fisher’s exact test.

When the whole data set was analyzed, the median follow-up period of the AC group was significantly shorter than that of the SCC group ($p = 0.02$). The number of dissected PALNs of the SCC group was almost significantly higher than that of the AC group ($p = 0.07$; Table 1). Patients with AC had a significantly higher rate of adjuvant chemotherapy than patients with SCC ($p < 0.01$; Table 1) and a significantly larger tumor size, 6 cm or more, than SCC patients ($p = 0.02$; Table 1). Of 82 patients, 29 (35.4%) had cancer recurrence. The recurrence rate of AC was significantly higher than that of SCC ($p = 0.04$). Of the 82 patients, 20 (24.4%) died, and the death rate of the AC group was significantly higher than that of the SCC group ($p = 0.05$, Table 1).

Univariate analysis indicated that histological type, PALN metastases, pelvic lymph node metastases, and tumor diameter were significantly associated with recurrence (Table 2). Adjuvant chemotherapy and cisplatin dose were close to significance for recurrence using univariate analysis (Table 2). We selected a tumor diameter of 6 cm or more from the results shown in Table 1.

All factors examined by univariate analysis were also evaluated using multivariate analysis. Multivariate analysis demonstrated that
| Background characteristics before propensity score matching | Background characteristics after propensity score matching |
|-------------------------------------------------------------|-------------------------------------------------------------|
| **Follow-up period, mo**                                      | **Follow-up period, mo**                                      |
| SCC (n = 60) 69.0 (33.3–122.3) AC (n = 22) 42.0 (28.8–61.5) | SCC (n = 22) 36.5 (27.3–75.0) AC (n = 22) 42.0 (28.8–61.5) |
| p value 0.02*                                                | p value 0.89                                                 |

| **Hb≥12 g/dL<sup>b</sup>**                                    | **Hb≥12 g/dL<sup>b</sup>**                                    |
|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------|
| SCC (n = 60) 12 (21.8) AC (n = 22) 5 (31.2)                                                     | SCC (n = 22) 6 (35.3) AC (n = 22) 5 (31.2)                                                   |
| p value 0.51                                                                                     | p value 1                                                                                      |

| **Age ≥60 y**                                             | **Age ≥60 y**                                             |
|------------------------------------------------------------|------------------------------------------------------------|
| SCC (n = 60) 11 (18.3) AC (n = 22) 6 (27.3)               | SCC (n = 22) 6 (27.3) AC (n = 22) 6 (27.3)               |
| p value 0.37                                               | p value 1                                                |

| **Blood loss ≥1000 g**                                    | **Blood loss ≥1000 g**                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 10 (16.7) AC (n = 22) 4 (18.2)               | SCC (n = 22) 3 (13.6) AC (n = 22) 4 (18.2)               |
| p value 1                                                  | p value 1                                                |

| **No. of dissected PALNs ≥6**                              | **No. of dissected PALNs ≥6**                              |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 55) 41 (68.3) AC (n = 16) 10 (45.5)              | SCC (n = 22) 11 (50.0) AC (n = 22) 11 (50.0)              |
| p value 0.07                                               | p value 1                                                |

| **Stromal invasion ≥2/3**                                   | **Stromal invasion ≥2/3**                                   |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 55 (94.8) AC (n = 16) 21 (95.5)               | SCC (n = 22) 20 (95.2) AC (n = 22) 21 (95.5)               |
| p value 1                                                  | p value 1                                                |

| **Charlson comorbidity Score ≥1**                           | **Charlson comorbidity Score ≥1**                           |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 6 (10) AC (n = 22) 2 (9.1)                    | SCC (n = 22) 1 (4.5) AC (n = 22) 2 (9.1)                   |
| p value 0.08                                               | p value 0.74                                              |

| **Year of surgery**                                        | **Year of surgery**                                        |
|-----------------------------------------------------------|-----------------------------------------------------------|
| Feb 1997 to Jul 2007 34 (56.7) 7 (31.8)                   | Feb 1997 to Jul 2007 5 (22.7) 7 (31.8)                     |
| Aug 2007 to Aug 2017 26 (43.3) 15 (68.2)                   | Aug 2007 to Aug 2017 17 (77.3) 15 (68.2)                   |
| p value 0.08                                               | p value 0.74                                              |

| **Adjuvant chemotherapy<sup>+</sup>**                       | **Adjuvant chemotherapy<sup>+</sup>**                       |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 12 (20) AC (n = 22) 15 (66.7)                 | SCC (n = 22) 6 (27.3) AC (n = 22) 15 (68.2)                |
| p value 0.0001*                                            | p value 0.01*                                             |

| **Pelvic ERT dose ≥45 Gy/25 Fr**                            | **Pelvic ERT dose ≥45 Gy/25 Fr**                            |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 41 (68.3) AC (n = 16) 10 (45.5)              | SCC (n = 22) 16 (72.7) AC (n = 22) 10 (45.5)               |
| p value 0.07                                               | p value 0.53                                              |

| **Cisplatin total dose ≥120 mg/m<sup>2</sup>**             | **Cisplatin total dose ≥120 mg/m<sup>2</sup>**             |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 41 (68.3) AC (n = 16) 10 (45.5)              | SCC (n = 22) 16 (72.7) AC (n = 22) 10 (45.5)               |
| p value 0.07                                               | p value 0.53                                              |

| **ICRT (vaginal vault)<sup>+</sup>**                        | **ICRT (vaginal vault)<sup>+</sup>**                        |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 16 (26.7) AC (n = 22) 4 (18.2)                | SCC (n = 22) 5 (22.7) AC (n = 22) 4 (18.2)                 |
| p value 0.57                                               | p value 1                                                |

| **IMRT<sup>+</sup>**                                        | **IMRT<sup>+</sup>**                                        |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 9 (15) AC (n = 22) 7 (31.8)                   | SCC (n = 22) 6 (27.3) AC (n = 22) 7 (31.8)                 |
| p value 0.11                                               | p value 1                                                |

| **PALN ERT<sup>+</sup>**                                    | **PALN ERT<sup>+</sup>**                                    |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 11 (18.3) AC (n = 22) 5 (22.7)                | SCC (n = 22) 5 (22.7) AC (n = 22) 5 (22.7)                 |
| p value 0.76                                               | p value 1                                                |

| **Tumor size and extent**                                   | **Tumor size and extent**                                   |
|-----------------------------------------------------------|-----------------------------------------------------------|
| ≥4 cm 43 (71.7) 20 (90.9)                                  | ≥4 cm 19 (86.4) 20 (90.9)                                  |
| p value 0.08                                               | p value 1                                                |

| **Vaginal involvement<sup>+</sup>**                         | **Vaginal involvement<sup>+</sup>**                         |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 60) 36 (60.0) AC (n = 22) 12 (54.5)               | SCC (n = 22) 10 (45.5) AC (n = 22) 12 (54.5)               |
| p value 0.80                                               | p value 0.76                                              |

| **PLN metastases+**                                        | **PLN metastases+**                                        |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 55) 35 (58.3) AC (n = 16) 12 (54.5)              | SCC (n = 22) 16 (72.7) AC (n = 22) 12 (54.5)               |
| p value 0.81                                               | p value 0.35                                              |

| **PALN metastases+**                                       | **PALN metastases+**                                       |
|-----------------------------------------------------------|-----------------------------------------------------------|
| SCC (n = 55) 5 (8.3) AC (n = 16) 5 (22.7)                 | SCC (n = 22) 4 (18.2) AC (n = 22) 5 (22.7)                 |
| p value 0.12                                               | p value 1                                                |

| **Prognosis**                                             | **Prognosis**                                             |
|-----------------------------------------------------------|-----------------------------------------------------------|
| Recurrence 17 (28.3) 12 (54.5)                             | Recurrence 11 (50.0) 12 (54.5)                             |
| Local recurrence 6 (10) 5 (22.7)                           | Local recurrence 4 (18.2) 5 (22.7)                         |
| Local and distant recurrence 0 (0) 2 (9.1)                 | Local and distant recurrence 0 (0) 2 (9.1)                 |
| Distant recurrence 11 (18.3) 5 (22.7)                       | Distant recurrence 7 (31.8) 5 (22.7)                       |
| Death 11 (18.3) 9 (40.9)                                   | Death 7 (31.8) 9 (40.9)                                   |
| p value 0.05*                                             | p value 0.76                                              |

Note: The follow-up period was analyzed by Mann-Whitney U test and the other (nominal) variables were analyzed by Fisher’s exact test.

Abbreviations: AC, adenocarcinoma; CI, confidence interval; ERT, external radiotherapy; Hb, hemoglobin; ICRT, intracavitary radiotherapy; IMRT, intensity-modulated radiation therapy; IQR, interquartile range; PALN, para-aortic lymph node; PLN, pelvic lymph node; SCC, squamous cell carcinoma.

<sup>a</sup> Values are given as median (interquartile range) or as number (percentage).

<sup>b</sup> Hemoglobin level at start of radiotherapy.

<sup>c</sup> Eleven women did not undergo radiotherapy and the total number was 71.

<sup>d</sup> Two women did not have data about stromal invasion and the SCC number was 58, and one woman did not have data about stromal invasion after propensity score matching.

<sup>*</sup> Significant according to the Mann-Whitney U test and Fisher’s exact test.
recurrence was associated with PALN metastases and tumor diameter of at least 6 cm (Table 2). Multivariate analysis also revealed that adjuvant chemotherapy had an inhibitory effect on recurrence (Table 2). The results in the univariate and multivariate analyses were not of a time-to-event design and we used logistic regression analyses with odds ratios instead of Cox proportional hazards regression analyses with hazard ratios (Table 2).

Kaplan–Meier plots using the whole data set are shown in Figure 2A (DFS) and Figure 2B (OS). The differences in DFS and OS between the SCC and AC groups were significant ($p = 0.01$ and $p = 0.03$, respectively).

Kaplan–Meier plots using propensity score matching are shown in Figure 2C (DFS) and Figure 2D (OS). The objective variable was the histological type of carcinoma. We chose PALN metastasis, tumor size, and cisplatin dose as the explanatory variables because these three variables were unbalanced between the SCC group and the AC group, and they were also clinically important from the result of the univariate analysis (Tables 1 and 2). Background characteristics after propensity score matching are also demonstrated in Table 1. Most of the imbalances of each factor before propensity score matching were corrected. However, the difference in the rate of adjuvant chemotherapy between the SCC and AC groups remained significant (Table 1). The differences in DFS and OS between the SCC and AC groups were not significant ($p = 0.65$ and $p = 0.63$, respectively).

The prognosis of the patients with recurrent disease after propensity score matching is shown in Figure 3. The survival difference between the SCC and AC groups was not significant ($p = 0.54$). The median survival with 95% confidence interval (CI) of the SCC and AC groups was 16.0 (95% CI 11.0–not applicable) months and 12.5 (95% CI 7.0–not available) months, respectively. There were 11 patients with recurrent disease among the SCC group (Table 1). Two of them underwent RT and chemotherapy, five underwent chemotherapy only, one underwent CCRT, and one underwent RT only. Two patients underwent no recurrent treatment. There were 12 patients with recurrent disease among the AC group (Table 1). Four of them underwent RT and chemotherapy, two underwent chemotherapy only, one underwent vaginal brachytherapy, and one underwent CCRT. Three patients underwent no recurrent treatment. The patient with the longest survival was a woman with cervical SCC who underwent RT for recurrent disease in the supraclavicular lymph nodes. There was no evidence of disease for 53 months after treatment of the recurrence.

Complications requiring long-term treatment or surgical treatment are indicated in Table 3. Thirty-five (42.7%) patients had troublesome complications and 21 (25.7%) required hospital admission and/or surgery (grade II or higher complications by the Clavien–Dindo classification\textsuperscript{13}; Table 3).

| Factor                  | Recurrence n/N (%) | Univariate analysis | Multivariate analysis | p value | p value |
|-------------------------|--------------------|---------------------|-----------------------|---------|---------|
|                         | OR (95% CI)        | p value             | OR (95% CI)           |         |         |
| Adjuvant chemotherapy   |                    |                     |                       |         |         |
| Reference               | 16/55 (29.1)       | 2.26 (0.87–5.87)    | 0.093                 | 0.15 (0.02–0.99) | 0.049*  |
| +                       | 13/27 (48.1)       |                     |                       |         |         |
| Cisplatin ≥120 mg/m\textsuperscript{2} |             | 0.40 (0.16–1.03)    | 0.057                 | 0.38 (0.09–1.64) | 0.195  |
| Reference               | 15/31 (48.4)       |                     |                       |         |         |
| +                       | 14/51 (27.5)       |                     |                       |         |         |
| Pelvic ERT dose         |                    |                     |                       |         |         |
| <45 Gy/25 Fr Reference  | 10/22 (45.5)       | 0.56 (0.21–1.51)    | 0.250                 | 0.87 (0.18–4.28) | 0.860  |
| ≥45 Gy/25 Fr            | 19/60 (31.7)       |                     |                       |         |         |
| Histological type       |                    |                     |                       |         |         |
| SCC                     | 17/60 (28.3)       | 3.04 (1.11–8.33)    | 0.031*                | 2.52 (0.62–10.30) | 0.198  |
| AC                      | 10/22 (45.5)       |                     |                       |         |         |
| PALN metastases −       | 21/72 (29.2)       | 9.71 (1.90–49.60)   | 0.006*                | 35.80 (3.11–413.00) | 0.004*  |
| +                       | 8/10 (80.0)        |                     |                       |         |         |
| PLN metastases −        | 8/35 (22.9)        | 2.73 (1.03–7.24)    | 0.044*                | 1.47 (0.40–5.43) | 0.567  |
| +                       | 21/47 (44.7)       |                     |                       |         |         |
| Tumor diameter ≥6 cm    |                    |                     |                       |         |         |
| Reference               | 15/62 (24.2)       | 7.31 (2.39–22.40)   | 0.001*                | 19.80 (3.47–113.00) | 0.001*  |
| +                       | 14/20 (70.0)       |                     |                       |         |         |

**Table 2** Univariate and multivariate analyses of recurrence using logistic regression.

| Abbreviations: AC, adenocarcinoma; CI, confidence interval; ERT, external radiotherapy; OR, odds ratio; PALN, para-aortic lymph node; PLN, pelvic lymph node; SCC, squamous cell carcinoma.

*Significant according to logistic regression analysis on univariate and multivariate analyses.

**DISCUSSION**

In Asian countries including Japan, RAH might be a feasible alternative for clinical FIGO Stage IIB cervical cancer.\textsuperscript{14–16} One of the reasons is that preoperative and postoperative occurrence of
parametrial involvement is relatively low.\textsuperscript{14} Consequently, we had the opportunity to investigate Stage pT\textsubscript{II}B AC as well as SCC. Five-year DFS and 5-year OS (0.736, 95% CI 0.599–0.832, and 0.801, 95% CI 0.668–0.885, respectively) of patients with Stage pT\textsubscript{II}B SCC among the whole population in the present study seemed comparable with previous results (0.767, 95% CI 0.716–0.818, and 0.747, 95% CI 0.694–0.800, respectively) obtained with primary CCRT for clinical FIGO Stage IB\textsubscript{2} to IIB cervical SCC.\textsuperscript{17} In this previous study, the results of the neoadjuvant chemotherapy (NAC) plus RAH group were inferior to those of the primary CCRT group.\textsuperscript{17} In a Japanese prospective study of cervical SCC with one AC case that included FIGO Stage IIB disease, OS in the NAC plus RAH group was inferior to that in the primary RAH group.\textsuperscript{18} Some populations did not respond to chemotherapy in NAC studies, and NAC could cause treatment delay in non-responders.

In the present study, the proportion of patients who underwent adjuvant chemotherapy in the AC group was significantly higher than that in the SCC group, even after propensity score matching, because one of the indications of adjuvant chemotherapy was AC with PALN involvement. A previous study including 46 patients with clinical FIGO Stage IIB cervical AC concluded that postoperative RT/CCRT might not suffice as adjuvant treatment for patients with
Stage IB1 to IIB cervical AC compared with patients with SCC, and suggested the potential role of adjuvant chemotherapy for women with cervical cancer, particularly those with AC.\(^{19}\)

The strengths of this study include its focus on patients who underwent RAH for bulky Stage pTIIB cervical cancer and its comparison of Stage pTIIB AC with Stage pTIIB SCC. However, there were some limitations to this study, including its retrospective nature and the small size of the AC group. There were 60 cases in the SCC group but only 22 in the AC group. More AC cases might need to be collected in the future.

Unfortunately, there have been no prospective studies comparing RAH plus adjuvant therapy with primary CCRT for clinical FIGO Stage IIB AC with Stage pTIIB SCC. However, there have also been few reports on primary RT/CCRT for bulky clinical FIGO Stage IIB cervical AC. For example, in a study of primary RT for AC in 15 patients with clinical FIGO Stage II cervical cancer, FIGO Stage IIA cases and FIGO Stage IIB cases were not distinguished.\(^{20}\) Other studies on clinical FIGO Stage IIB cervical cancer included only one AC patient and three AC patients, respectively, in the CCRT group.\(^{16,21}\)

Recently, a study investigating the prognosis of cervical SCC and cervical AC reported that the overall mortality of clinical FIGO Stage IIB cervical AC was 2.46 of the adjusted hazard ratio (95% CI 1.34–4.53) in 55 patients who received curative definitive CCRT compared with 66 patients who received curative surgery.\(^{11}\) In our study after propensity score matching, more than 40% of the patients had tumors with diameters of 6 cm or more. It is difficult to cure such large Stage pTIIB cervical tumors regardless of whether the tumor is SCC or AC. However, the controlling ability of RAH for Stage pTIIB cervical AC seemed to be comparable with that for Stage pTIIB cervical SCC in the whole population was well controlled by RAH plus adjuvant therapy. Bulky Stage pTIIB cervical AC had a similar 5-year DFS and OS to Stage pTIIB cervical SCC after propensity score matching when patients underwent RAH plus adjuvant therapy. Bulky Stage pTIIB cervical cancer is hard to cure. However, considering that there are few reports of conventional primary RT/CCRT for bulky clinical FIGO Stage IIB cervical AC

### Table 3

|                  | Total | SCC | AC |
|------------------|-------|-----|----|
|                  | n = 82| n = 60| n = 22 |
| Total            | 35 (42.7)\(^a\) | 28 (46.7)\(^a\) | 7 (31.8)\(^a\) |
| Urological       | 6 (7.3) | 3 (5.0) | 3 (13.6) |
| Long-lasting CIC | 6 (7.3) | 3 (5.0) | 3 (13.6) |
| Intestinal       | 14 (17.1) | 13 (21.7) | 1 (4.5) |
| Intestinal       | 9 (11.0)\(^b\) | 9 (15.0) | 0 (0) |
| Intestinal       | 5 (6.1)\(^b\) | 4 (6.7) | 1 (4.5) |
| Lymphedema       | 15 (18.3) | 12 (20.0) | 3 (13.6) |
| Lymphedema       | 8 (9.8) | 5 (8.3) | 3 (13.6) |
| Recurrent lymphedema | 3 (3.7)\(^b\) | 3 (5.0) | 0 (0) |
| Lymphedema       | 4 (4.9)\(^b\) | 4 (6.7) | 0 (0) |
| Complication     | 21 (25.7) | 20 (33.3) | 1 (4.5) |

Abbreviations: AC, adenocarcinoma; CIC, continuous intermittent catheterization; SCC, squamous cell carcinoma.

\(^a\)Among women with plural complications, the representative or most important complication is indicated.

\(^b\)The suffix “d” indicates that a follow up is required to comprehensively evaluate the outcome and related long-term quality of life.

In conclusion, Stage pTIIB cervical SCC and RAH plus adjuvant therapy could be used to treat clinical FIGO Stage IIB AC with parametrial involvement in countries in which RAH is performed on FIGO Stage IIB cervical cancer. Now that we can evaluate parametrial invasion by MRI before treatment, we await studies investigating the OS of patients with FIGO Stage IIB cervical AC with parametrial invasion when they are treated with primary RT/CCRT. Recently, a study reported that 5-year OS was approximately 75% in 12 patients with clinical FIGO Stage IIB cervical AC who were treated with chemo-carbon-ion RT.\(^{22}\) However, we await the long-term results and information on the toxicities of this potentially promising treatment modality.

---

**Figure 3** Cumulative OS curves of SCC and AC after recurrence. AC, adenocarcinoma; CI, confidence interval; OS, overall survival; SCC, squamous cell carcinoma.
with parametrial invasion indicated by MRI, RAH could be an alternative treatment option for Stage pT1B cervical AC because AC disease control by RAH was comparable with that of SCC.

ACKNOWLEDGMENTS
We thank H. Nikki March and Cathel Kerr from Edanz Group (https://en-author-services.edanzgroup.com/ac) for editing drafts of this manuscript.

CONFLICTS OF INTEREST
The authors have no conflicts of interest.

AUTHOR CONTRIBUTIONS
MO conceived and designed the study, analyzed the data, and drafted the manuscript. RN collected the data. MS supervised the statistical analysis. Ke So, Ku Sh, and TS made critical comments on the manuscript. All authors contributed to the revision of the article and approved the final version of the manuscript.

ORCID
Masao Okadome https://orcid.org/0000-0001-6179-7103

REFERENCES
1. Rose PG, Bundy BN, Watkins EB, et al. Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. N Engl J Med. 1999;340(15):1144-1153.
2. Grigsby PW, Perez CA, Kuske RR, et al. Adenocarcinoma of the uterine cervix: lack of evidence for a poor prognosis. Radiother Oncol. 1988;12(4):289-296.
3. Rose PG, Java JJ, Whitney CW, Stehman FB, Lanciano R, Thomas GM. Locally advanced adenocarcinoma and adenosquamous carcinomas of the cervix compared to squamous cell carcinomas of the cervix in gynecologic oncology group trials of cisplatin-based chemoradiation. Gynecol Oncol. 2014;135(2):208-212.
4. Chen J-L, Huang C-Y, Huang Y-S, et al. Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/adenosquamous carcinoma and squamous cell carcinoma of cervix treated with definitive radiotherapy. Acta Obstet Gynecol Scand. 2014;93(7):661-668.
5. Zhou J, Wu S-G, Sun J-Y, et al. Comparison of clinical outcomes of squamous cell carcinoma, adenocarcinoma, and adenosquamous carcinoma of the uterine cervix after definitive radiotherapy: a population-based analysis. J Cancer Res Clin Oncol. 2017;143(1):115-122.
6. Lee J-Y, Kim YT, Kim S, et al. Prognosis of Cervical Cancer in the Era of Concurrent Chemoradiation from National Database in Korea: A Comparison between Squamous Cell Carcinoma and Adenocarcinoma. PLoS One. 2015;10(12):e0144887.
7. Fuji S, Takakura K, Matsumura N, et al. Anatomic identification and functional outcomes of the nerve sparing Okabayashi radical hysterectomy. Gynecol Oncol. 2007;107(1):4-13.
8. Matsuo K, Shimada M, Aoki Y, et al. Comparison of adjuvant therapy for node-positive clinical stage IB-IIB cervical cancer: Systemic chemotherapy versus pelvic irradiation. Int J Cancer. 2017;141(5):1042-1051.
9. Matsuo K, Shimada M, Yamaguchi S, et al. Association of radical hysterectomy surgical volume and survival for early-stage cervical cancer. Obstet Gynecol. 2019;133(6):1086-1098.
10. Koh WJ, Abu-Rustum NR, Bean S, et al. Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(1):64-84.
11. Wu SY, Huang EY, Lin H. Optimal treatments for cervical adenocarcinoma. Am J Cancer Res. 2019;9(6):1224-1234.
12. Piver MS, Rutledge F, Smith JP. Five classes of extended hysterectomy for women with cervical cancer. Obstet Gynecol. 1974;44(2):265-272.
13. Dindo D, Demartines N, Clavien PA. Classification of surgical complications: a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann Surg. 2004;240(2):205-213.
14. Yuan L, Guo J, Zhang X, Chen M, Xu C, Yao L. Feasibility of radical hysterectomy in women with FIGO stage IBIB cervical cancer: an observation study of 10-year experience in a tertiary center. Onco Targets Ther. 2018;11:5527-5533.
15. Song X, Han Y, Shao Y, Gu W, Pei H, Jiang J. Assessment of local treatment modalities for FIGO stage IB-IIB cervical cancer: A propensity-score matched analysis based on SEER database. Sci Rep. 2017;7(1):3175.
16. Tomita N, Mizuno M, Makita C, et al. Propensity score analysis of radical hysterectomy versus definitive chemoradiation for FIGO stage IIB cervical cancer. Int J Gynecol Cancer. 2018;28(8):1576-1583.
17. Gupta S, Maheshwari A, Parab P, et al. Neoadjuvant chemotherapy followed by radical surgery versus concomitant chemotherapy and radiotherapy in patients with stage IB2, IIA, or IIB squamous cervical cancer: a randomized controlled trial. J Clin Oncol. 2018;36(16):1548-1555.
18. Katsumata N, Yoshikawa H, Kobayashi H, et al. Phase III randomised controlled trial of neoadjuvant chemotherapy plus radical surgery vs radical surgery alone for stages IB2, IIA2, and IIB cervical cancer: a Japan Clinical Oncology Group trial (JCOG 0102). Br J Cancer. 2013;108(10):1957-1963.
19. Shimada M, Nishimura R, Nagawa T, et al. Comparison of the outcome between cervical adenocarcinoma and squamous cell carcinoma patients with adjuvant radiotherapy following radical surgery: SGSG/TGCU Intergroup Surveillance. Mol Clin Oncol. 2013;1(4):780-784.
20. Nakano T, Arai T, Morita S, Oka K. Radiation therapy alone for adenocarcinoma of the uterine cervix. Int J Radiat Oncol Biol Phys. 1995;32(5):1331-1336.
21. Yamashita H, Okuma K, Kawana K, et al. Comparison between conventional surgery plus postoperative adjuvant radiotherapy and concurrent chemoradiation for FIGO stage IIB cervical carcinoma: a retrospective study. Am J Clin Oncol. 2010;33(6):583-586.
22. Okonogi N, Wakatsuki M, Kato S, et al. Significance of concurrent use of weekly cisplatin in carbon-ion radiotherapy for locally advanced adenocarcinoma of the uterine cervix: A propensity score-matched analysis. Cancer Med. 2020;9(4):1400-1408.

How to cite this article: Okadome M, Nagayama R, Shimokawa M, Sonoda K, Shimamoto K, Saito T. Prognosis of bulky pT1B cervical cancer treated by radical hysterectomy comparing adenocarcinoma with squamous cell carcinoma using propensity score matching. Int J Gynecol Obstet. 2021;153:56–63. https://doi.org/10.1002/ijgo.13451